CN117343117A - 一种新型甜菊糖苷衍生物莱鲍迪苷m8的制备方法 - Google Patents
一种新型甜菊糖苷衍生物莱鲍迪苷m8的制备方法 Download PDFInfo
- Publication number
- CN117343117A CN117343117A CN202311183537.1A CN202311183537A CN117343117A CN 117343117 A CN117343117 A CN 117343117A CN 202311183537 A CN202311183537 A CN 202311183537A CN 117343117 A CN117343117 A CN 117343117A
- Authority
- CN
- China
- Prior art keywords
- rebaudioside
- glycosyltransferase
- ugt94e13
- compound
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930188195 rebaudioside Natural products 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 title abstract description 9
- RPYRMTHVSUWHSV-CUZJHZIBSA-N rebaudioside D Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RPYRMTHVSUWHSV-CUZJHZIBSA-N 0.000 claims abstract description 59
- 108700023372 Glycosyltransferases Proteins 0.000 claims abstract description 39
- 102000051366 Glycosyltransferases Human genes 0.000 claims abstract description 39
- 108010043934 Sucrose synthase Proteins 0.000 claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 17
- 239000000758 substrate Substances 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 16
- 235000003599 food sweetener Nutrition 0.000 claims description 14
- 239000003765 sweetening agent Substances 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 13
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 claims description 13
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000348 glycosyl donor Substances 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- 239000001512 FEMA 4601 Substances 0.000 claims description 3
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 238000006555 catalytic reaction Methods 0.000 claims description 3
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 3
- 235000019203 rebaudioside A Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 239000004384 Neotame Substances 0.000 claims description 2
- RLLCWNUIHGPAJY-RYBZXKSASA-N Rebaudioside E Natural products O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O)[C@H](CO)O1)[C@]1(C)[C@@H]2[C@@](C)([C@@H]3[C@@]4(CC(=C)[C@@](O[C@@H]5[C@@H](O[C@@H]6[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O6)[C@H](O)[C@@H](O)[C@H](CO)O5)(C4)CC3)CC2)CCC1 RLLCWNUIHGPAJY-RYBZXKSASA-N 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- RLLCWNUIHGPAJY-SFUUMPFESA-N rebaudioside E Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLLCWNUIHGPAJY-SFUUMPFESA-N 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 241001409321 Siraitia grosvenorii Species 0.000 claims 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 claims 1
- 229960005164 acesulfame Drugs 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 abstract description 36
- 238000006206 glycosylation reaction Methods 0.000 abstract description 33
- 230000013595 glycosylation Effects 0.000 abstract description 27
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 238000003786 synthesis reaction Methods 0.000 abstract description 8
- 238000007036 catalytic synthesis reaction Methods 0.000 abstract description 2
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 abstract 1
- 238000009412 basement excavation Methods 0.000 abstract 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002436 one-dimensional nuclear magnetic resonance spectrum Methods 0.000 abstract 1
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 abstract 1
- 229940032084 steviol Drugs 0.000 abstract 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 24
- 108090000790 Enzymes Proteins 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 235000019202 steviosides Nutrition 0.000 description 15
- 229930006000 Sucrose Natural products 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000005720 sucrose Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000004383 Steviol glycoside Substances 0.000 description 12
- 235000019411 steviol glycoside Nutrition 0.000 description 12
- 229930182488 steviol glycoside Natural products 0.000 description 12
- 150000008144 steviol glycosides Chemical class 0.000 description 12
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 239000013592 cell lysate Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000007791 liquid phase Substances 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000007865 diluting Methods 0.000 description 7
- 239000013049 sediment Substances 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- -1 glucanases Proteins 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 241000157835 Gardenia Species 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011033 desalting Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JUJWROOIHBZHMG-QYKNYGDISA-N 2-deuteriopyridine Chemical compound [2H]C1=CC=CC=N1 JUJWROOIHBZHMG-QYKNYGDISA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000008163 sugars Chemical group 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000001551 total correlation spectroscopy Methods 0.000 description 1
- SPOMEWBVWWDQBC-UHFFFAOYSA-K tripotassium;dihydrogen phosphate;hydrogen phosphate Chemical compound [K+].[K+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O SPOMEWBVWWDQBC-UHFFFAOYSA-K 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/34—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/36—Terpene glycosides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
- A23L27/37—Halogenated sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/56—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01013—Sucrose synthase (2.4.1.13)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种新型甜菊糖苷衍生物莱鲍迪苷M8的制备方法,属于生物催化合成领域。本发明通过挖掘得到一种具有催化莱鲍迪苷D单糖基化活性的糖基转移酶UGT94E13,通过LC‑MS、1D和2D NMR波谱对产物的完整结构进行分析,得到全新的的甜菊醇糖苷——莱鲍迪苷D单糖基化衍生物莱鲍迪苷M8。本发明将糖基转移酶UGT94E13与蔗糖合酶AtSuSy构建偶联反应,实现以莱鲍迪苷D为底物高效催化合成莱鲍迪苷M8,高效合成5.71g/L的莱鲍迪苷M8,莱鲍迪苷M8产率达到88.52%,为莱鲍迪苷M8的生产提供了一条高效且绿色的新途径。
Description
技术领域
本发明涉及一种新型甜菊糖苷衍生物莱鲍迪苷M8的制备方法,属于生物催化合成技术领域。
背景技术
近年来,全世界范围内龋齿、肥胖症、糖尿病、高血压、心血管疾病的患病风险不断增加,因此,消费者对低热量或无热量甜味剂的需求不断增加。从甜叶菊中提取得到的甜菊糖苷因其高甜度(是蔗糖的50-450倍)、无热量、安全,被认为是目前最具吸引力的甜味剂。此外,甜叶菊苷还被发现具有重要的药理活性,如降糖、降压、利尿、抗炎、抗肿瘤和免疫调节作用。如今已从甜叶菊中发现六十余种甜菊糖苷,其中甜菊糖(占叶子干重的5-10%)和莱鲍迪苷A(占叶子干重的2-4%)是含量最丰富的两种成分,也是目前市面上商用的甜菊糖苷类添加剂的主要成分。不幸的是,食用甜菊糖苷后会带有一种挥之不去的苦味,这也限制了甜菊糖苷更成功的商业化应用。
目前已发现甜菊糖苷C-13位和/或C-19位所连接的糖的数量和位置能明显影响甜味和口感,但具体的结构与甜味的关系还未得到充分解析。解决这一问题较为有效的方法是在不同位置引入一个单一的糖基单元。因此,相关研究者对甜菊糖苷进行了许多的化学与生物修饰,以阐明甜菊糖苷结构与功能的关系并期望能获得具有更优甜味品质的甜菊糖苷。到目前为止,已有多种酶被报道用于甜菊糖苷的糖基化修饰,如环糊精糖基转移酶、葡聚糖酶、半乳糖苷酶、葡萄糖苷酶、果糖苷酶等。但这些酶存在产率较低、产物混杂等缺点,并且往往还会在底物上同时引入多个糖基单元,相较而言,UDP-糖基转移酶具有高转化率和区域选择性。因此,挖掘UDP-糖基转移酶以实现对莱鲍迪苷D不同位置的单糖基化,对阐明甜菊糖苷结构与甜味品质的关系具有重要意义。
发明内容
为解决上述问题,本发明挖掘来自栀子的糖苷转移酶UGT94E13催化莱鲍迪苷D合成单糖基化衍生物莱鲍迪苷M8,该酶在大肠杆菌中能够实现可溶性高效表达,并且在尿苷二磷酸葡萄糖(UDPG)存在的情况下具有催化莱鲍迪苷D合成莱鲍迪苷M8的活性。并通过构建尿苷二磷酸葡萄糖UDPG循环再生体系,利用大肠杆菌裂解液实现高效生物合成莱鲍迪苷M8,为莱鲍迪苷M8的工业化应用提供了一种有效的方法。
为了解决上述技术问题,本发明的技术方案如下:
本发明的第一个目的是提供一种化合物,所述化合物的化学结构为13-[(2-O-β-D-glucopyranosyl-3-O-(6-O-β-D-glucopyranosyl)-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]ent-kaur-16-en-19-oic acid-[(2-O-β-D-glucopyranosyl-β-D-glucopyranosyl)ester],化学结构式如下所示:
本发明的第二个目的是提供一种甜味剂组合物,所述甜味剂组合物含有所述化合物。
在一种实施方式中,所述甜味剂组合物还含有莱鲍迪苷A、莱鲍迪苷D、莱鲍迪苷E、莱鲍迪苷O、菊糖、β-葡聚糖、罗汉果糖、木糖醇、赤藓糖醇、麦芽糖醇、三氯蔗糖、阿斯巴甜、安赛蜜或纽甜中的一种或多种。
在一种实施方式,所述甜味剂组合物中还含有矫味剂。
在一种实施方式,所述矫味剂为核糖、木糖及木糖醇、葡萄糖、山梨醇、乳糖、蔗糖、帕拉金糖、海藻糖、麦芽糊精或淀粉、乳酸、苹果酸和柠檬酸中的一种或多种。
本发明的第三个目的是提供所述化合物或所述甜味剂组合物在制备食品或药品中的应用。
本发明的第四个目的是提供所述化合物或所述甜味剂组合物在制备甜味剂中的应用。
本发明的第五个目的是提供一种食品,所述食品中含有所述化合物或所述甜味剂组合物。
本发明的第六个目的是提供一种合成所述化合物的重组菌,所述重组菌过表达糖基转移酶UGT94E13,所述糖基转移酶UGT94E13的氨基酸序列的NCBI登录号为MN944055.1。
在一种实施方式中,所述糖基转移酶UGT94E13的核苷酸序列的NCBI登录号为ARU08119.1。
在一种实施方式中,所述重组菌还表达蔗糖合酶。
在一种实施方式中,所述蔗糖合酶的氨基酸序列可以是任意来源的具有蔗糖合酶活性的氨基酸序列。
在一种实施方式中,所述蔗糖合酶的氨基酸序列的NCBI登录号为NP_001031915。
在一种实施方式中,所述蔗糖合酶的核苷酸序列如SEQ ID NO.1所示。
在一种实施方式中,所述重组菌以大肠杆菌为宿主细胞。
在一种实施方式中,所述重组菌以pET系列为表达载体。
在一种实施方式中,所述重组菌以pET-21b(+)为表达载体。
本发明的第三个目的是提供一种催化合成所述化合物的方法,所述方法包括(a)或(b):
(a)以UDP-葡萄糖为糖基供体,以莱鲍迪苷D为底物,利用糖基转移酶UGT94E13和蔗糖合酶催化反应;
(b)发酵培养所述重组菌,收集菌液,破碎后收集上清,以UDP-葡萄糖为糖基供体,以莱鲍迪苷D为底物,利用上清进行催化反应。
在一种实施方式中,所述催化反应的条件为:以2~10mmol/L莱鲍迪苷D、0-800mmol/L蔗糖、5-25%(v/v)DMSO、80~120mmol/L K2HPO4-KH2PO4缓冲液,80~120mmol/LNaCl为反应体系,20-50℃糖基化反应0-48h。
在一种实施方式中,所述缓冲液pH为5.5-9.0。
本发明还提供了糖基转移酶UGT94E13或所述重组菌或所述方法在制备所述化合物或含有所述化合物的产品中的应用。
有益效果:
本发明以UDPG为糖基供体,以莱鲍迪苷D为底物,利用糖基转移酶UGT94E13催化合成一个全新的甜菊醇糖苷——莱鲍迪苷D单糖基化衍生物莱鲍迪苷M8,为食品产业提供了一个新的甜味剂。为阐明甜菊糖苷结构与甜味的关系提供了一个新的类似物。进一步的,本发明将糖基转移酶UGT94E13与蔗糖合酶AtSuSy联用,构建UDPG循环再生体系。通过偶联反应体系条件优化,实现利用5.64g/L(5mmol/L)莱鲍迪苷D以88.52%的高产率合成5.71g/L的莱鲍迪苷M8。本发明构建的重组菌株共表达栀子来源的糖基转移酶和拟南芥来源的蔗糖合酶,利用重组菌株诱导表达后制备得到的细胞裂解液催化莱鲍迪苷D合成莱鲍迪苷M8,无需添加糖基供体,也不需要额外使用细胞通透剂,显著降低成本且绿色环保。
附图说明
图1显示糖基转移酶UGT94E13催化莱鲍迪苷D产生莱鲍迪苷M8的生物合成途径。
图2为实施例2中糖基转移酶UGT94E13蛋白表达及纯化分析。泳道1:Marker;泳道2:无IPTG诱导表达样品;泳道3:粗酶液;泳道4:粗酶液上清;泳道5:粗酶液沉淀;泳道6:纯化穿透液;泳道7:洗涤杂蛋白质样品;泳道8:目的蛋白质洗脱样品。
图3为实施例3中糖基转移酶UGT94E13催化莱鲍迪苷D合成莱鲍迪苷M8的UPLC分析图。
图4为实施例3中莱鲍迪苷D糖基化反应产物莱鲍迪苷M8质谱分析。
图5为实施例4中产物莱鲍迪苷M8的核磁共振波谱分析氢谱。
图6为实施例4中产物莱鲍迪苷M8的核磁共振波谱分析碳谱。
图7为实施例4中产物莱鲍迪苷M8的核磁共振波谱分析COSY谱。
图8为实施例4中产物莱鲍迪苷M8的核磁共振波谱分析TOCSY谱。
图9为实施例4中产物莱鲍迪苷M8的核磁共振波谱分析HSQC谱。
图10为实施例4中产物莱鲍迪苷M8的核磁共振波谱分析HMBC谱。
图11为实施例4中产物莱鲍迪苷M8的核磁共振波谱分析ROESY谱。
图12为实施例6中UGT94E13-AtSuSy糖基化偶联反应裂解液蛋白表达分析。泳道1:Marker;泳道2:无IPTG诱导表达样品;泳道3:粗酶液;泳道4:粗酶液上清;泳道5:粗酶液沉淀。
图13为实施例7中pH对糖基化偶联反应缓冲溶液的影响。
图14为实施例8中温度对糖基化偶联反应的影响。
图15为实施例9中DMSO浓度对糖基化偶联反应的影响。
图16为实施例10中蔗糖浓度对糖基化偶联反应的影响。
图17为实施例11中反应时间对糖基化偶联反应的影响。
具体实施方式
以下结合说明书附图和具体实施例来进一步说明本发明,但实施例并不对本发明做任何形式的限定。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
除非特别说明,以下实施例所用试剂和材料均为市售商品或者可以通过已知方法制备。
下述实施例中涉及到的培养基:
LB固体培养基:10g/L蛋白胨,5g/L酵母粉,10g/L NaCl,20g/L琼脂粉。
2×YT液体培养基:16g/L蛋白胨,10g/L酵母粉,5g/L NaCl。
下述实施例中涉及到的方法:
糖基转移酶酶学性质的测定:糖基转移酶UGT94E13对莱鲍迪苷D的动力学分析是在200μL反应体系中进行的,反应体系含有5mM UDPG、10mM MnCl2、50mM Tris pH 8.0和5μg纯化蛋白样品(糖基转移酶UGT94E13),莱鲍迪苷D的浓度为0-0.5mM。反应温度为35℃,反应时间为2h,反应混合物在35℃下反应2h;然后在95℃条件下加热5min淬灭反应,并将反应混合物用2倍体积甲醇稀释;20000×g离心5min以去除沉淀物;取上层液体用0.22μm滤膜过滤后用于UPLC分析。
酶活的定义:在1h内合成1μM莱鲍迪苷M8所需的酶量。
莱鲍迪苷M8的产率的测定:利用二甲基亚砜溶解糖基化产物,制得5mM的母液。再利用甲醇稀释母液配制一系列浓度的溶液:0、0.1、0.25、0.5、0.75、1mM。所制溶液经0.22μM滤膜过滤后,利用UPLC对标准溶液进行分析,获得莱鲍迪苷M8浓度标准曲线方程为y=2601014.39560x-3188.57143,R2=0.99877。根据标准曲线换算得到莱鲍迪苷M8的产率。产率=莱鲍迪苷M8实际产量/莱鲍迪苷M8理论产量。
Waters Acquity UPLC系统:采用BEH C18 1.7μM色谱柱(2.1×50mm),液相条件为:有机相--乙腈、水相--超纯水;流速0.3mL/min;柱温40℃;紫外检测波长210nm;检测程序:0-1min 15%有机相、6min40%有机相、7-8min 15%有机相。
实施例1糖基转移酶UGT94E13基因的获取和重组菌株的构建
从Genbank中下载栀子糖基转移酶氨基酸序列(登录号:MN944055.1)及核苷酸序列(登录号:ARU08119.1),由亦欣生物科技有限公司进行基因合成并连接至载体pET-21b(+)的多克隆酶切位点,得到重组质粒pET-21b(+)-UGT94E13。
将所得质粒pET-21b(+)-UGT94E13进行测序鉴定并转化至大肠杆菌E.coli BL21(DE3)感受态细胞中,采用含有100μg/mL氨苄青霉素的LB固体平板进行筛选,得到重组菌株E.coli BL21(DE3)pET-21b(+)-UGT94E13。
实施例2重组菌株的诱导表达及目的蛋白纯化
将实施例1中构建的重组菌株E.coli BL21(DE3)pET-21b(+)-UGT94E13接种至含有100μg/mL氨苄青霉素的1L 2×YT液体培养基中,在135rpm,37℃条件下培养至OD600为0.6-0.8后,培养温度降至18℃,加入终浓度为0.1mmol/L的异丙基-β-硫代半乳糖苷(IPTG),诱导培养8h。
将诱导表达的菌液离心(7000rpm,7min,4℃),弃上清,收集菌体。将菌体用裂解缓冲液(50mmol/LTris-HCl pH 8.0,300mmol/L NaCl,10mmol/L咪唑,10%甘油)按照1g菌体每10mL裂解缓冲液进行重悬。利用高压匀浆机进行破碎,然后将破碎后的菌液进行离心(40000×g,30min),取上清即获得粗酶液。
将粗酶液利用Ni+柱进行亲和层析纯化,上样结束后,10倍体积裂解液冲洗杂蛋白,用洗脱缓冲液(50mmol/L Tris-HCl pH 8.0,300mmol/L NaCl,250mmol/L咪唑,10%甘油)进行目的蛋白洗脱。收集洗脱的目的蛋白,通过脱盐柱(HistrpTM 5mL Desalting)进行脱盐,脱盐缓冲液(25mmol/L Tris-HCl,150mmol/LNaCl,10%甘油)。脱盐后浓缩至10mg/mL,进行后续反应。纯化的蛋白通过10% SDS-PAGE凝胶电泳进行检测,结果见图2,成功获得目的条带清晰蛋白大小准确的纯酶。测得UGT94E13对莱鲍迪苷D的Km值为0.89±0.05mM,kcat值为0.33±0.08min-1。并测得纯酶UGT94E13的酶活为360mU/mg。
实施例3UGT94E13催化莱鲍迪苷D反应合成莱鲍迪苷M8的糖基化反应
将实施例2获得的纯化后的糖基转移酶UGT94E13用于糖基化反应(图1)。
糖基化反应在200μL反应体系中进行,反应体系如下:50mmol/L Tris pH 8.0,5mmol/L UDPG,10mmol/L MnCl2,0.5mmol/L莱鲍迪苷D,实施例2中所获得纯酶UGT94E13浓度为5μM。在35℃下反应4h。然后在95℃条件下加热5min淬灭反应,并将反应混合物用2倍体积甲醇稀释;20000×g离心5min以去除沉淀物;取上层液体用0.22μm滤膜过滤后用于UPLC和LC-MS分析。Waters Acquity UPLC系统采用BEH C18 1.7μM色谱柱(2.1×50mm),液相条件为:有机相-乙腈、水相-超纯水;流速0.3mL/min;柱温40℃;紫外检测波长210nm;检测程序:0-1min 15%有机相、6min 40%有机相、7-8min 15%有机相。
通过液相分析可得知,结果如图3所示,与莱鲍迪苷D标准品对比可知,在反应体系中有明显的新产物生成,并对反应混合物进行质谱(MS)分析(图4),LC-MS的负离子模式结果显示,在m/z 1289.5421处有一个[M-H]-离子的峰,对应分子式C56H90O33,表明产物是莱鲍迪苷D的单糖基衍生物。
实施例4新型莱鲍迪苷D单糖基化衍生物的结构鉴定
利用糖基转移酶UGT94E13用于大规模(100mL)糖基化反应制备新型衍生物,反应体系如下:2mM Reb D,10μM糖基转移酶,5mM UDPG,10mM MnCl2,50mM Tris pH8.0。反应混合物在35℃下反应24h,然后在95℃条件下加热5min淬灭反应,20000×g离心5min以去除沉淀物;取上层液体用0.22μm滤膜过滤后,使用半制备高效液相色谱系统进行纯化,系统采用Shim-pack GIST C18色谱柱(10×250mm,5μm,SHIMADZU,Japan),液相条件为:有机相--乙腈、水相--超纯水;流速5mL/min;时间程序:0-28min 23%有机相;28.5-30.5min 60%有机相;31-35min 23%有机相。柱温:40℃;紫外检测波长210nm。所得样品用氘代吡啶溶解,通过1D(1H和13C)和2D NMR(COSY、TCOSY、HSQC、HMBC和ROESY)波谱对产物的完整结构进行分析。用Bruker Avance III 600MHz spectrometer(Bruker BioSpin,Karlsruhe,Germany)收集数据,1H谱检测频率为600MHz,13C谱为151MHz。1H-NMR具有典型的甜菊糖苷信号特征。化学位移小于2.8ppm的峰来自于萜烯苷元,化学位移从3.6-6.3ppm的峰来自于糖环。
从1H和1H-13C HSQC波谱显示在δH 6.29(δC 93.45)、δH 5.53(δC 104.28)、δH 5.46(δC 105.43)、δH 5.25(δC 104.37)、δH 5.06(δC 97.38)、δH 4.81(δC 104.26)存在6个异常质子,证实产物的结构中存在6个糖单元。同时,在δH 6.29(7.3Hz)、δH 5.53(7.8Hz)、δH5.46(7.7Hz)、δH 5.25(7.9Hz)、δH5.06(7.5Hz)、δH 4.81(7.7Hz)处观察到高J偶极矩表明6个葡萄糖残基均为β构型。通过1D和2D HMR对新衍生物的H和C的化学位移进行了详细的归属(图5~图11),如表1所示。确定新产物为莱鲍迪苷D二萜核心的C-13位的葡萄糖基上通过β-1,6-键连接了一个葡萄糖基,将其命名为莱鲍迪苷M8。结构式为13-[(2-O-β-D-glucopyranosyl-3-O-(6-O-β-D-glucopyranosyl)-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]ent-kaur-16-en-19-oic acid-[(2-O-β-D-glucopyranosyl-β-D-glucopyranosyl)ester]。
表1 1H和13C化学位移归属表(pyridine-d5)
实施例5糖基转移酶和蔗糖合酶重组质粒及重组菌株的构建
从Genbank中下载来源于拟南芥的蔗糖合酶AtSuSy氨基酸序列(登录号:NP_001031915)以及其核酸序列(登录号:NM_001036838.2),由亦欣生物科技有限公司进行大肠杆菌偏好的密码子优化及基因合成。将编码蔗糖合酶基因AtSuSy连接至pACYCDuet-1的多克隆酶切位点,构建重组质粒pACYCDuet-1-AtSuSy,将所得质粒进行测序鉴定,并与pET-21b(+)-UGT94E13共转化至大肠杆菌E.coli BL21(DE3)感受态细胞中,采用含有100μg/mL氨苄青霉素和34μg/mL氯霉素的LB固体平板进行筛选,得到重组菌株E.coli BL21(DE3)UGT94E13-AtSuSy。
实施例6糖基转移酶和蔗糖合酶偶联反应细胞裂解液的制备
将实施例5中构建的重组菌株E.coli BL21(DE3)UGT94E13-AtSuSy接种于添加含有100μg/mL氨苄青霉素和34μg/mL氯霉素的5L 2×YT培养基中,37℃、135rpm振荡培养。待菌体生长至OD600值为0.6-0.8时,降温至18℃,向其中添加终浓度为0.2mM IPTG,继续在18℃诱导表达8h后,7000×g离心7min,收集菌体,菌体用裂解缓冲液(100mM K2HPO4-KH2PO4(KPi)pH 8.0,100mM NaCl)洗涤三次然后重悬。细胞用高压匀浆机破碎。立即用40000×g离心30min,除去细胞碎片。取上清即获得偶联反应细胞裂解液。并进行蛋白胶检测。
结果如图12所示,结果显示糖基转移酶和蔗糖合酶都能够良好表达。细胞裂解液中蛋白浓度利用Nano-Drop 2000UV-Vis分光光度计进行测定。制备的细胞裂解液进行分装后-80℃保存,或作为粗酶液直接用于偶联反应。
实施例7pH对糖基转移酶和蔗糖合酶糖基化偶联反应的影响
将糖基化偶联反应体系置于不同pH值的缓冲液中进行反应,测定pH对糖基转移酶和蔗糖合酶糖基化偶联反应的影响,选择的缓冲液为100mM KPi pH 5.5-8.0(含有100mMNaCl)、100mM Tris pH 7.0-9.0(含有100mM NaCl)。
将按照实施例6所述制备偶联反应细胞裂解液,糖基化偶联反应体系为1mL,其中含有40mg/mL粗酶,5mM Reb D,200mM蔗糖,5%二甲基亚砜(v/v)。反应混合物在35℃下反应3h;然后在95℃条件下加热5min淬灭反应,并将反应混合物用4倍体积甲醇稀释;20000×g离心5min以去除沉淀物;取上层液体用0.22μm滤膜过滤后用于UPLC分析。液相检测方法按照实施例3中所述进行,并计算莱鲍迪苷M8的产率,结果显示当缓冲液为100mmol/L KPi pH8.0,100mmol/L NaCl时,莱鲍迪苷M8的产率可以达到32%以上(图13)。
实施例8温度对糖基转移酶和蔗糖合酶糖基化偶联反应的影响
将糖基化偶联反应体系置于不同温度(20~50℃)中进行反应,测定温度对糖基转移酶和蔗糖合酶糖基化偶联反应的影响。
按照实施例6所述制备偶联反应细胞裂解液,偶联反应体系为1mL,其中含有40mg/mL粗酶,5mM Reb D,200mM蔗糖,5%二甲基亚砜(v/v),100mM KPi pH 8.0(含有100mMNaCl)。反应混合物在20-50℃下反应3h;然后在95℃条件下加热5min淬灭反应,并将反应混合物用4倍体积甲醇稀释;20000×g离心5min以去除沉淀物;取上层液体用0.22μm滤膜过滤后用于UPLC分析。液相检测方法按照实施例3中所述进行,并计算莱鲍迪苷M8的产率,结果显示当温度在40~45℃时,莱鲍迪苷M8的产率可以达到43%以上(图14)。
实施例9DMSO浓度对糖基转移酶和蔗糖合酶糖基化偶联反应的影响
将糖基化偶联反应体系中添加不同浓度的DMSO(5%-25%(v/v))中进行反应,测定DMSO浓度对糖基转移酶和蔗糖合酶糖基化偶联反应的影响。
按照实施例6所述制备偶联反应细胞裂解液,偶联反应体系为1mL,其中含有40mg/mL粗酶,5mM Reb D,200mM蔗糖,二甲基亚砜(5%-25%(v/v)),100mM KPi pH 8.0(含有100mM NaCl)。反应混合物在35℃下反应3h;然后在95℃条件下加热5min淬灭反应,并将反应混合物用4倍体积甲醇稀释;20000×g离心5min以去除沉淀物;取上层液体用0.22μm滤膜过滤后用于UPLC分析。液相检测方法按照实施例3中所述进行,并计算莱鲍迪苷M8的产率,结果显示当DMSO浓度在5%~15%(v/v)时,莱鲍迪苷M8的产率维持稳定(图15)。
实施例10蔗糖浓度对糖基转移酶和蔗糖合酶偶联反应的影响
将糖基化偶联反应体系中添加不同浓度的蔗糖(50-800mmol/L)中进行反应,测定蔗糖浓度对糖基转移酶和蔗糖合酶糖基化偶联反应的影响。
按照实施例6所述制备偶联反应细胞裂解液,偶联反应体系为1mL,其中含有40mg/mL粗酶,5mM Reb D,0-800mM蔗糖,5%二甲基亚砜,100mM KPi pH 8.0(含有100mM NaCl)。反应混合物在35℃下反应3h;然后在95℃条件下加热5min淬灭反应,并将反应混合物用4倍体积甲醇稀释;20000×g离心5min以去除沉淀物;取上层液体用0.22μm滤膜过滤后用于UPLC分析。液相检测方法按照实施例3中所述进行,并计算莱鲍迪苷M8的产率,结果显示当蔗糖浓度为400mmol/L时,莱鲍迪苷M8的产率可以达到34%以上(图16)。
实施例11反应时间对糖基转移酶和蔗糖合酶偶联反应的影响
将糖基化偶联反应体系反应不同的时间(0-24h),测定蔗糖浓度对糖基转移酶和蔗糖合酶糖基化偶联反应的影响。
按照实施例6所述制备偶联反应细胞裂解液,偶联反应体系为20mL,其中含有40mg/mL粗酶,5mM Reb D,400mM蔗糖,5%二甲基亚砜(v/v),100mM KPi pH 8.0(含有100mMNaCl),45℃条件下反应,反应时间优化范围为0-24h。在一系列时间点时(0-24h,时间间隔为3h)取样,然后在95℃条件下加热5min淬灭反应,并将反应混合物用4倍体积甲醇稀释;20000×g离心5min以去除沉淀物;取上层液体用0.22μm滤膜过滤后用于UPLC分析。液相检测方法按照实施例3中所述进行,并计算莱鲍迪苷M8的产率,结果显示最终在反应12h时,以5mmol/L莱鲍迪苷D浓度时,以88.52%的产率获得5.71g/L的莱鲍迪苷M8(图17)。
实施例12莱鲍迪苷M8的甜味测试
使用莱鲍迪苷D作为对照进行莱鲍迪苷M8的甜味测试。莱鲍迪苷D样品购自毕得医药。其中莱鲍迪苷M8纯度为98%。
SA402B电子舌系统用于糖基化产物的甜味分析。将20mg Reb D或20mg糖基化产物充分溶解在50mL超纯水(浓度为400ppm)中,配制甜味分析所用样品溶液;SA402B电子舌系统采用脂质膜传感器(GL1)和参比电极(Ag/AgCl),使用时提前利用参比溶液(30mM KCl和0.3mM酒石酸)浸泡传感器至少24h;然后将活化后的传感器在参比溶液中平衡后依次浸没于参比溶液和样品溶液中,分别测得膜电势Vr和Vs,按照如下公式计算味觉信号值(R),每个样品溶液循环测定4次,取后三次数据的平均值作为测试结果:
R=Vs-Vr (1)
如表2所示,分析结果表明Reb M8的R(味觉信号值)值高于Reb D,即Reb M8的甜味高于Reb D,说明C-13位的单β-1,6-O-糖基化均能有效改善Reb D的甜味性质,为新型甜菊糖苷类天然甜味剂的开发提供了重要信息。
表2 Reb M8和Reb D的电子舌分析
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (10)
1.一种化合物,其特征在于,所述化合物的化学结构式如下所示:
2.一种甜味剂组合物,其特征在于,含有权利要求1所述的化合物。
3.根据权利要求2所述的甜味剂组合物,其特征在于,含有莱鲍迪苷A、莱鲍迪苷D、莱鲍迪苷E、莱鲍迪苷O、菊糖、β-葡聚糖、罗汉果糖、木糖醇、赤藓糖醇、麦芽糖醇、三氯蔗糖、阿斯巴甜、安赛蜜或纽甜中的一种或多种。
4.权利要求1所述化合物,或权利要求2或3所示甜味剂组合物在制备食品或药品中的应用。
5.权利要求1所述化合物,或权利要求2或3所示甜味剂组合物在制备甜味剂中的应用。
6.一种合成权利要求1所述化合物的重组菌,其特征在于,表达糖基转移酶UGT94E13;所述糖基转移酶UGT94E13氨基酸序列的NCBI登录号为MN944055.1。
7.根据权利要求6所述的重组菌,其特征在于,所述重组菌还表达蔗糖合酶。
8.根据权利要求7所述的重组菌,其特征在于,所述蔗糖合酶的氨基酸序列可以是任意来源的具有蔗糖合酶活性的氨基酸序列。
9.一种合成权利要求1所述化合物的方法,其特征在于,所述方法包括(a)或(b):
(a)以UDP-葡萄糖为糖基供体,以莱鲍迪苷D为底物,利用糖基转移酶UGT94E13和蔗糖合酶催化反应;
(b)发酵培养权利要求6~8任一所述重组菌,收集菌液,破碎后收集上清,以UDP-葡萄糖为糖基供体,以莱鲍迪苷D为底物,利用上清进行催化反应。
10.糖基转移酶UGT94E13或权利要求6~8任一所述重组菌或权利要求9所述方法在制备权利要求1所述化合物或含有权利要求1所述化合物的产品中的应用;所述糖基转移酶UGT94E13氨基酸序列的NCBI登录号为MN944055.1。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2023110384948 | 2023-08-17 | ||
CN202311038494 | 2023-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117343117A true CN117343117A (zh) | 2024-01-05 |
Family
ID=89358435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311183537.1A Pending CN117343117A (zh) | 2023-08-17 | 2023-09-13 | 一种新型甜菊糖苷衍生物莱鲍迪苷m8的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117343117A (zh) |
-
2023
- 2023-09-13 CN CN202311183537.1A patent/CN117343117A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101404728B1 (ko) | 스테비오사이드로부터 리바우디오사이드 a를 제조하는 방법 | |
KR101971818B1 (ko) | 스테비올 글리코시드의 재조합 생산 | |
EP2645847B1 (en) | Microbial production of natural sweeteners, diterpenoid steviol glycosides | |
CN110191643B (zh) | 甜菊醇糖苷的生物合成生产及其工艺 | |
CN107567492B (zh) | Udp-糖基转移酶 | |
Simkhada et al. | Genetic engineering approach for the production of rhamnosyl and allosyl flavonoids from Escherichia coli | |
CN113549664A (zh) | 高纯度甜菊醇糖苷 | |
CN110358795A (zh) | 高纯度的甜菊醇糖苷 | |
CN106834389B (zh) | 一种重组菌催化莱鲍迪甙a制备莱鲍迪甙m2的方法 | |
CN110699373B (zh) | 尿苷二磷酸葡萄糖高产菌株及其应用 | |
WO2023087518A1 (zh) | 一种利用糖基转移酶高效生物合成莱鲍迪苷d的方法 | |
AU2018200459A1 (en) | Recombinant production of steviol glycosides | |
CN117343117A (zh) | 一种新型甜菊糖苷衍生物莱鲍迪苷m8的制备方法 | |
Ping et al. | Efficient synthesis of rebaudioside D2 through UGT94D1-catalyzed regio-selective glycosylation | |
CN115418358B (zh) | 一种糖基转移酶及其应用 | |
CN117106685A (zh) | 一种利用糖基转移酶高效生物合成莱鲍迪苷m2的方法 | |
CN115449514A (zh) | 一种β-1,2-糖基转移酶及其应用 | |
Yang et al. | Highly efficient synthesis of mono-β-1, 6-Glucosylated Rebaudioside A derivative catalyzed by glycosyltransferase YjiC | |
CN113584110A (zh) | 一种以罗汉果醇为底物生物合成罗汉果糖苷v的工程菌株的构建及其应用 | |
CN111511909B (zh) | 应用节杆菌属微生物制备转果糖基甜菊苷的方法 | |
CN115433249A (zh) | 一种新型甜菊糖苷衍生物莱鲍迪苷l2的制备方法 | |
CN115433702A (zh) | 一种利用糖基转移酶高效生物合成莱鲍迪苷d2的方法 | |
CN115478060B (zh) | 一种糖基转移酶及其应用 | |
KR20190002364A (ko) | 레반수크라아제를 이용한 루부소사이드-프락토사이드의 합성 방법 | |
CN114875054B (zh) | 一种酶法制备糖基化甜菊糖苷类化合物的方法及其衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240525 Address after: No.19, Renmin South Road, Lingui District, Guilin City, Guangxi Zhuang Autonomous Region Applicant after: GUILIN LAYN NATURAL INGREDIENTS Corp. Country or region after: China Address before: No. 66 Jinghui East Road, Xinwu District, Wuxi City, Jiangsu Province, 214000 (Jiangnan University National University Science Park) Applicant before: Jiangnan University Country or region before: China |